The Polish company has already managed to obtain the vaccine antigen in laboratories.
Mabion representatives announced that the implementation of the contract with the American developer of the coronavirus vaccine – Novavax – is going according to plan. The production line is almost ready, they assured.
Mabion is implementing the first stage of the contract with Novavax for the production of a vaccine component against Covid-19. carrying out the process on a laboratory scale. At the same time, the commercial production stage is agreed. According to Sławomir Jaros, who sits in the management, the Polish company has already managed to obtain the vaccine antigen in laboratories.
As he added, the production line owned by the company is sufficient for the production of a vaccine antigen and is almost for the production of a vaccine – Mabion is waiting only for single devices for commercial production.
- The devices I mentioned do not limit our ability to scale up the process in the first stage of cooperation and execution of test series – he explained. This is important information as Novavax declares its willingness to use the full scale of Mabion’s manufacturing capabilities.
Mabion also announced that it had received an order from Novavax, under the existing framework contract for the COVID-19 vaccine, for the implementation of raw materials under the March agreement on technology transfer and technical tests.
Pietruszkiewicz said that the details of the contract with Novavax are confidential, but when it comes to the ordered raw materials, they should be sufficient for serial production approximately until the middle of next year, so – in the opinion of the management board – this is a significant scale.
- It is definitely a big step in our cooperation with Novavax. Such an order confirms that they see us as a long-term partner – added Pietruszkiewicz.